# The Neuro & Alzheimer's Pipeline - Week of May 31, 2026: Biogen's Derenersen Misses Primary, Hits AD Subgroup

> Neuro and Alzheimer's pipeline newsletter for May 24–31, 2026. Biogen's anti-tau Derenersen misses its Phase II primary but flags an AD subgroup signal, while the blood-biomarker complex keeps racing ahead and big-company launch commentary stays conspicuously quiet.


## The Neuro & Alzheimer's Pipeline

### Week of May 24–31, 2026

---

```request-access
variant: ghost
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

Biogen's tau program got a second act this week, even as the broader trial result disappointed. The diagnostic side of the field keeps racing ahead while the therapeutic side grinds, and the most striking thing about the week's commentary is what it left out: almost nothing on the major launch ramps. Below is the synthesis.

## TL;DR

- Biogen's anti-tau Derenersen missed its Phase II primary in the broad CELIA trial, but a pre-specified Alzheimer's subgroup showed slowing of clinical decline, and Biogen says it will engage regulators. Messy, but it keeps post-Leqembi optionality alive.
- The blood-biomarker drumbeat got louder: serum p-tau217 now looks operationally comparable to plasma, and a separate academic team rolled out a 21-protein early-detection panel claiming an 88% cost saving vs. PET.
- Big-company commentary was unusually quiet. No fresh coverage in the last week on Kisunla, Leqembi/IQLIK, Roche trontinemab, AbbVie emraclidine, KarXT/Cobenfy, or CMS coverage. That silence is itself a signal (see "What changed vs last week").

## What's new

**Biogen's Derenersen, the tau program just got a second act.** NeurologyLive's Mind Moments News Minute flagged top-line Phase II CELIA results for Biogen's anti-tau therapy Derenersen: missed the primary endpoint, but a pre-specified AD subgroup showed slowing of clinical decline and Biogen says it will engage regulators on next steps. News read by host Marco Maglio. The narrator also noted "increasing discussion" of stacking anti-amyloid plus anti-tau in combination. For BIIB this is messy (subgroup wins don't ship drugs) but it keeps optionality on the post-Leqembi pipeline alive and complicates the simple bear story that BIIB has nothing behind Leqembi.

**Serum p-tau217 now looks as good as plasma, diagnostic friction is dropping fast.** Dr. Barack Arslan of Sahlgrenska University Hospital, Gothenburg, told Clinical Chemistry Podcast that serum p-tau217 performs comparably to plasma p-tau217 (different cutoffs, but similar diagnostic value), and that the marker "increases up to two decades before the onset of clinical symptoms." A practicing clinical chemist who ran the assay study. He also flagged that newer brain-derived p-tau217 assays may improve specificity by reducing peripheral-source confounding. This is the bull case for the entire blood-diagnostic complex (C2N PrecivityAD2, Roche Elecsys, Quanterix, Fujirebio, LabCorp/Quest): serum better than plasma means easier draws, easier shipping, easier integration into primary-care workflow.

**A new 21-protein panel claims 88% cost savings vs. PET.** Dr. Yuanbing Jiang, inventor of PlasmarkAD, said on AUTM on the Air that the panel hit 96% accuracy in Hong Kong Chinese and Spanish cohorts, was licensed to private Cognitect Limited, and has been used in 1,000+ patients within six months of its 2025 Hong Kong launch. Inventor and licensor. His sharpest line: with anti-amyloid mAbs only working in early disease, biomarker-based detection "is not an optional option, it's the key for diagnosis." Take the 96%/88% numbers with the usual academic-claim salt (single-developer data, non-US cohorts) but the directional message lines up with what Roche, Lilly, and C2N have been telling the buy-side.

**A KOL's framing of the mAb class: "a beginning, not the solution."** Dr. Gil Rubinovich of UCSF's Alzheimer's Disease Research Center gave the longest think-piece this week on Healthy Dialogue, characterizing lecanemab and donanemab as showing roughly 30% slowing of cognitive/functional decline, roughly 30–35% reduction in MCI-to-dementia conversion, and ARIA in roughly 20–30% of patients in Phase 3. A practicing dementia specialist. His most important call: pre-symptomatic prevention trials with both antibodies are expected to read out in roughly 2027–2028, i.e., the next real catalyst for the class isn't a sub-Q launch, it's whether you can treat patients before symptoms appear at all.

## The debate

**Bulls.** Sub-Q lecanemab (IQLIK) is in market, sub-Q donanemab is in development, serum p-tau217 is now operationally comparable to plasma, and a 21-protein panel is claiming 88% cheaper diagnosis than PET. Stack those and the diagnostic-to-treatment funnel goes from "specialist + PET + IV infusion every two weeks" to "PCP draws blood + monthly autoinjector." Add Rubinovich's reminder that 2027–2028 prevention readouts could re-position the class from disease-*modifying* to disease-*preventing*, and the multi-billion franchise math gets very real.

**Bears.** Rubinovich himself called the current generation "a beginning, not the solution": 30% slowing isn't 30% reversal, and 20–30% ARIA hasn't disappeared because the drug is sub-Q. Derenersen missed its primary, which is a reminder that tau remains an unforgiving target; subgroup salvage stories almost never become approved drugs without a confirmatory Phase III. And we don't have a single piece of operator evidence this week about Kisunla or Leqembi/IQLIK *unit volumes*. When no operator wants to talk about the ramp, that's its own data point.

> The cleanest summary of this week: the diagnostic side is racing ahead, the therapeutic side is still grinding.

---

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Stocks in play

**Biogen (BIIB)**: *Bull:* Derenersen AD-subgroup signal keeps the post-Leqembi pipeline alive; combination amyloid plus tau narrative resurfaces. *Bear:* A Phase II primary miss is a primary miss; Eisai still owns the lead Leqembi economics. *Next catalyst:* Biogen's regulator engagement on Derenersen path forward, plus any Leqembi/IQLIK quarterly volume update.

**Eli Lilly (LLY)**: *Bull:* Rubinovich's framing of 2027–2028 pre-symptomatic prevention readouts puts donanemab in line for a category-redefining indication. *Bear:* No fresh color on Kisunla launch trajectory this week; silence isn't a positive when you're carrying launch expectations. *Next catalyst:* Pre-symptomatic donanemab trial updates and any sub-Q development milestone.

**Eisai (4523.T)**: *Bull:* IQLIK sub-Q lecanemab plus serum p-tau217 evidence both reduce friction on the Leqembi ramp. *Bear:* No operator color on Leqembi/IQLIK volumes this week. *Next catalyst:* Quarterly Leqembi sales disclosure.

**Roche (ROG.SW / RHHBY)**: *Bull:* Elecsys p-tau217 is well-positioned if serum-comparable-to-plasma evidence continues to stack. *Bear:* No trontinemab or bepranemab color this week, a clean miss on the most-watched non-amyloid program. *Next catalyst:* Trontinemab Phase III enrollment/initiation updates.

**Quanterix (QTRX)**: *Bull:* Every "serum p-tau217 is good enough" data point widens the addressable Simoa market. *Bear:* Not named in this week's coverage; competitive entries from academic groups (PlasmarkAD) and large reference labs continue. *Next catalyst:* Reference-lab adoption metrics.

**Lantheus (LNTH) and GE HealthCare (GEHC)**: *Bull:* If serum p-tau217 only handles screening, PET still anchors confirmatory diagnosis and trial enrollment. *Bear:* The 88% cost-savings claim from PlasmarkAD, if generalized, is precisely the structural threat to amyloid-PET volume. *Next catalyst:* PET volume disclosure in Q2 prints.

**Option Care Health (OPCH)**: Not mentioned this week; infusion-center thesis remains a function of IV mAb persistence vs. sub-Q migration. *Bear watch:* every IQLIK autoinjector script is, mechanically, a script not going to an infusion chair.

## Read-throughs

- **Blood diagnostics (QTRX, C2N, Roche Elecsys, Fujirebio, LabCorp/Quest):** Two of this week's episodes were diagnostic-focused. Direction of travel is unmistakable: easier specimen handling, earlier detection, lower cost.
- **PET imaging (LNTH, GEHC):** Direct competitive threat from cheaper blood panels picks up a fresh data point this week; watch utilization trends.
- **Infusion centers (OPCH):** Quiet this week; the IQLIK sub-Q migration is the structural story.
- **Tau / non-amyloid:** The Derenersen miss is a category data point, not just a BIIB story. Roche bepranemab, Eisai E2814, Lilly remternetug all get re-rated on this news, though none surfaced in commentary this week.
- **Broader CNS (KarXT/Cobenfy, Vyalev, Huntington's):** Zero coverage in the last week.

---

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## What changed vs last week

- **New:** First confirmation of the Derenersen Phase II miss plus AD subgroup signal.
- **Reinforced:** Serum p-tau217 approximately equals plasma p-tau217 narrative; academic blood-diagnostic competition continues to widen.
- **Notable silences (a real signal):** No coverage in the last week of Kisunla launch trajectory, Leqembi/IQLIK ramp, Roche trontinemab, bepranemab, AbbVie emraclidine, Vyalev, KarXT/Cobenfy, or CMS NCD/CED policy. When the buy-side and the journalists go quiet on a launch in its first eighteen months, that is itself a data point worth carrying into next week's KOL calls.

## Sources

- [Healthy Dialogue, *A New Era in Dementia: Advances in Diagnostic Blood Tests, Novel Drugs, and the Power of Lifestyle Changes*, May 21, 2026 (Dr. Gil Rubinovich, UCSF)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhyYoUlZgsoFOw0eavjbw7bX-2BPzukVnjSbqj1DVgHJ9D9B-2FCxnfkFRaCvxUXn3hnOsedb5N-2Bh9fI2owXx-2F3ImuVzrmvbFeEk9nM0yobDZ9cYw-3D-3DLa-K_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXlr1lZMzOOvXL12vwKuw0rKS8ZZDU0DtUgIPhKqOAXkn42mvZOA-2BsewKM6MjYvIZTbAPi4GR3BD98LupmzYU37nyS9TBlg5JWgCz76P4Gc-2FNs5guw5MI7tmX2qn8lC2dyhbWKQ23OGXw-2B1k11PZLgB8IrVfjThgLHv1bjHwdo4GQ-3D-3D)
- [Clinical Chemistry Podcast, *Diagnostic Value of Serum p-tau217 in Alzheimer Disease*, May 18, 2026 (Dr. Barack Arslan, Sahlgrenska University Hospital; host Bob Barrett)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjFSVFClNNSqG9-2FNPqtd6EHEQtm-2Fl-2BAvc3BXOeJbejbsztH-2FTG1VGD5LxoXzgN786foG0Cqm5GjcI0e-2Bi7Bc-2BCtpClz-2FylsjAkjAtLyC1L3sg-3D-3DVWbt_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXlr1lZMzOOvXL12vwKuw0rKS8ZZDU0DtUgIPhKqOAXkhsKZfWpSm2X-2FmSskGWDqCKC7g81OUzysVfWnYH8ZWyqXmPH09IYuvxUf8o2SM4aOKBXYVx9TLVAyTahlfP0j-2FcFRn-2FrC-2F67toWJ9N7V-2FYkPzYHTHDuHMEGW66IYNvpoAg-3D-3D)
- [NeurologyLive Mind Moments, *New AASM Guidance on Combination Treatment for Chronic Insomnia* (News Minute segment), May 29, 2026 (host Marco Maglio)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgDYlOD-2B3yCJYAd-2Bzl-2FWFfftVxupamc67VljTvz2wJMtSRuWLBp0vpfXVDdJ29JFAjuugJZPBw-2F3RL6S26KhaWqiiJMxX2hE-2BauAiAGnh2MJA-3D-3DAmOT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXlr1lZMzOOvXL12vwKuw0rKS8ZZDU0DtUgIPhKqOAXknkHAGnIW8cNaaHOLbCxesdo0pPteBeqq7axvEk5vG4KGVCSQl7dufZJcuLPpoIdHEX7aV8FhTA3Z3ZAotvGwm2EbLM2a50tIafM19SwtBCxmM-2ByCvFlLKgDh7fiOw59zA-3D-3D)
- [AUTM on the Air, *Detecting Alzheimer's Earlier with a Simple Blood Test*, May 27, 2026 (Dr. Yuanbing Jiang; host Lisa Mueller)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhZL9YJR67HdlMp05vhhlAYy0U2U-2Bqjy3Z7Z-2F8aLfFOU6UvuE4SKV4HGwSxyRvDDamX0Rl74C5UlLRedOWvqDcYKagUfcmYyJeofLUz-2FVH8lg-3D-3DurnE_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXlr1lZMzOOvXL12vwKuw0rKS8ZZDU0DtUgIPhKqOAXkjhWzMu2qsRt6Ft-2F4rs-2Bq2lf6eB2eGJnOcElcAYzu40tHtAuQkzpgBtXWYJ1F-2FvL4E3oLs6mOdZi8LB6ijvpWIl6eRW7fX7T3VdRQjqClor3GsfR-2Fp8sncj4iRpaypqPpw-3D-3D)

```request-access
variant: banner
heading: Run your own corpus.
description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage.
buttonText: Request access
```